Company Focus
Summit Therapeutics
Latest Summit Therapeutics News
Biotechnology
Chinese biopharmaceutical firm Akeso has reported that its bispecific antibody ivonescimab improved overall survival (OS) compared with Keytruda (pembrolizumab), from US pharma major Merck & C, in previously untreated lung cancer patients, at a pre-specified interim analysis of the Phase III HARMONi-2 trial assessed by an independent data monitoring committee. 4 September 2026
Oncology News
Latest News & Features of interest to Summit Therapeutics
Pharmaceutical
Swiss pharma major Novartis is under public pressure to overhaul its board after two late-stage trial failures in the space of a few days triggered the steepest share price fall in the company's history. David Samra, managing director at USA-based fund manager Artisan Partners, told Reuters on Thursday that the board needs far stronger oversight of acquisitions. 11 September 2026
Biotechnology
The UK's National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Johnson & Johnson's Darzalex (daratumumab) with bortezomib, lenalidomide and dexamethasone (D-VRd), followed by daratumumab-lenalidomide maintenance, for previously untreated multiple myeloma in transplant-eligible adults. 10 September 2026
Biotechnology
US clinical-stage biotech Tyra Biosciences yesterday announced initial results from SURF302, its Phase II study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). 10 September 2026
Biotechnology
USA-based Solstice Oncology has launched with a $225 million Series A financing to advance porustobart, a second-generation, Fc-enhanced CTLA-4 antibody, into neoadjuvant treatment of colon cancer. 10 September 2026
Pharmaceutical
The US Food and Drug Administration (FDA) yesterday granted accelerated approval for German pharma major Bayer’s Hyrnuo (sevabertinib), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test. 10 September 2026
Biotechnology
US clinical stage biotech Callio Therapeutics has announced the appointment of Zachary (Zach) Hornby as chief executive (CEO). 10 September 2026
Pharmaceutical
US biotech company TwoStep Therapeutics has secured Food and Drug Administration (FDA) clearance to begin human testing of its lead cancer candidate, TS-104, alongside an oversubscribed $62.5 million series A financing. The San Carlos, California-based firm said patient enrollment in a first-in-human Phase I trial should begin before the end of the year. 10 September 2026
Biotechnology
Bristol Myers Squibb, the US pharma major, has reported positive topline Phase II results for arlocabtagene autoleucel (arlo-cel; BMS-986393), an investigational GPRC5D-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma who had already failed four drug classes. 9 September 2026
Biotechnology
US biotech major Amgen has announced landmark results from the Phase III DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically-significant and clinically-meaningful improvement in overall survival with Imdelltra (tarlatamab-dlle) in combination with AstraZeneca’s Imfinzi (durvalumab) compared to durvalumab alone. 9 September 2026
Biotechnology
US biopharma Inhibrx Biosciences has reported that its OX40 agonist INBRX-106, combined with Merck & Co's Keytruda (pembrolizumab) nearly doubled response rates against pembrolizumab alone in a randomized Phase II trial in head and neck squamous cell carcinoma (HNSCC). 9 September 2026
Latest In Brief for Summit Therapeutics
Pharmaceutical
Spanish drugmaker PharmaMar has announced that health authorities in Canada, Qatar and South Korea have approved Zepzelca (lurbinectedin) in combination with atezolizumab (Roche’s Tecentriq) for the maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide. 25 August 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze